Clinical trials in Tilburg – page 2

144 clinical trials in Tilburg, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Tilburg at a glance

144

clinical trials

Research sites1

Quick filters

144 trials in Tilburg

Open in trial search

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Colitis ulcerative

Recruiting

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Golimumab
Sponsor:Janssen Cilag International

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:AZD0901
Sponsor:AstraZeneca AB

Contact Research Centre

Rheumatoid arthritis

Recruiting

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Sint Maartenskliniek Stichting

Contact Research Centre

Chronic lymphocytic leukaemia+2

Recruiting

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Venetoclax
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Guselkumab
Sponsor:Janssen Cilag International

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Colitis ulcerative

Recruiting

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational

A study of LY4268989 and mirikizumab in adults with moderately to severely active ulcerative colitis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Mirikizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Tilburg

What the registry says about research in the country

01 Gastrointestinal Diseases

Research focusing on innovative treatments for inflammatory bowel diseases, particularly evaluating new therapies for Crohn's Disease and Ulcerative Colitis. Studies include long-term safety assessments and combination therapy approaches.

Ulcerative Colitis Treatment Studies
Crohn's Disease Management
Gastric Cancer Interventions

Advanced clinical trials examining novel therapeutic agents and their effectiveness in treating moderate to severe digestive conditions.

02 Cardiovascular Research

Comprehensive studies addressing cardiovascular disease management, including investigations into peripheral arterial disease and innovative approaches to reducing cardiovascular events.

Lipoprotein Management
Arterial Disease Treatment
Stroke Prevention Studies

Trials focusing on both preventive measures and treatment strategies for various cardiovascular conditions.

03 Oncology Studies

Innovative research in cancer treatment, including breast cancer, colorectal cancer, and advanced therapeutic approaches for various tumor types.

Breast Cancer Therapies
Colorectal Cancer Treatment
Leukemia Management

Studies evaluating targeted therapies and combination treatments for various stages of cancer.

04 Immunology and Inflammation

Research examining autoimmune conditions and inflammatory disorders, with particular focus on novel therapeutic approaches and long-term disease management.

Rheumatic Disease Studies
Immunotherapy Trials
Anti-inflammatory Treatments

Investigations into innovative treatment options for chronic inflammatory conditions.

Back to the Netherlands All countries